scholarly journals Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome

2020 ◽  
Vol 9 (9) ◽  
pp. 3039 ◽  
Author(s):  
Dean Chan Pin Yin ◽  
Jaouad Azzahhafi ◽  
Stefan James

Risk scores are widely used in patients with acute coronary syndrome (ACS) prior to treatment decision-making at different points in time. At initial hospital presentation, risk scores are used to assess the risk for developing major adverse cardiac events (MACE) and can guide clinicians in either discharging the patients at low risk or swiftly admitting and treating the patients at high risk for MACE. During hospital admission, risk assessment is performed to estimate mortality, residual ischemic and bleeding risk to guide further in-hospital management (e.g., timing of coronary angiography) and post-discharge management (e.g., duration of dual antiplatelet therapy). In the months and years following ACS, long term risk can also be assessed to evaluate current treatment strategies (e.g., intensify or reduce pharmaceutical treatment options). As multiple risk scores have been developed over the last decades, this review summarizes the most relevant risk scores used in ACS patients.

2018 ◽  
Vol 71 (7) ◽  
pp. 538-544
Author(s):  
Pedro J. Flores-Blanco ◽  
Francisco Cambronero-Sánchez ◽  
Sergio Raposeiras-Roubin ◽  
Emad Abu-Assi ◽  
Gunnar Leithold ◽  
...  

2020 ◽  
Vol 9 (7) ◽  
pp. 2064
Author(s):  
Gregorio Tersalvi ◽  
Luigi Biasco ◽  
Giacomo Maria Cioffi ◽  
Giovanni Pedrazzini

Inhibition of platelet function by means of dual antiplatelet therapy (DAPT) is the cornerstone of treatment of acute coronary syndrome (ACS). While preventing ischemic recurrences, inhibition of platelet function is clearly associated with an increased bleeding risk, a feared complication that may lead to significant morbidity and mortality. Since bleeding risk management is intrinsically associated with therapeutic adjustments undertaken during the whole clinical history of patients with acute coronary syndrome, single decisions taken from the very first day to years of follow-up might be decisive. This review aims at providing a clinically oriented, patient-tailored approach in reducing the risk and manage bleeding complications in ACS patients treated with DAPT. The steps in clinical decision making from the day of ACS to follow-up are analyzed. New treatment strategies to enhance the safety of DAPT are also described.


2012 ◽  
Vol 1 (3) ◽  
pp. 222-231 ◽  
Author(s):  
Emad Abu-Assi ◽  
Sergio Raposeiras-Roubin ◽  
Pamela Lear ◽  
Pilar Cabanas-Grandío ◽  
Mar Girondo ◽  
...  

2018 ◽  
Vol 254 ◽  
pp. 10-15 ◽  
Author(s):  
Sergio Raposeiras-Roubín ◽  
Jonas Faxén ◽  
Andrés Íñiguez-Romo ◽  
Jose Paulo Simao Henriques ◽  
Fabrizio D'Ascenzo ◽  
...  

2017 ◽  
Vol 58 (6) ◽  
pp. 406-415 ◽  
Author(s):  
Tamara Jakimov ◽  
Igor Mrdović ◽  
Branka Filipović ◽  
Marija Zdravković ◽  
Aleksandra Djoković ◽  
...  

2019 ◽  
Vol 33 (5) ◽  
pp. 523-532 ◽  
Author(s):  
Rita Pavasini ◽  
Elisa Maietti ◽  
Elisabetta Tonet ◽  
Giulia Bugani ◽  
Matteo Tebaldi ◽  
...  

2021 ◽  
Vol 10 (19) ◽  
pp. 4574
Author(s):  
Dávid Bauer ◽  
Petr Toušek

Defining the risk factors affecting the prognosis of patients with acute coronary syndrome (ACS) has been a challenge. Many individual biomarkers and risk scores that predict outcomes during different periods following ACS have been proposed. This review evaluates known outcome predictors supported by clinical data in light of the development of new treatment strategies for ACS patients during the last three decades.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
J Boeddinghaus ◽  
M Meier ◽  
T Nestelberger ◽  
P Lopez-Ayala ◽  
P.D Ratmann ◽  
...  

Abstract Background Clinical risk scores are recommended for formal risk stratification in patients presenting with suspected acute coronary syndrome (ACS). It is unknown, whether these scores still provide additional value in the era of high-sensitivity cardiac troponin (hs-cTn) compared to simple integrated clinical judgment. Purpose To evaluate the diagnostic and prognostic performance of integrated clinical judgment compared to clinical risk scores. Methods We prospectively enrolled patients presenting to the emergency department with symptoms suggestive of ACS such as acute chest discomfort. The primary prognostic endpoint was the composite of 30-day major adverse cardiac events (MACE) including all-cause death, life-threatening arrhythmia, cardiogenic shock, acute myocardial infarction (AMI, including the index event), and urgent coronary revascularization and was adjudicated by two independent cardiologists. The performance of five well-established formal risk scores (T-MACS, HEART, GRACE, TIMI, and EDACS) for the prediction of 30-day MACE was directly compared with simple integrated clinical judgment for the ACS likelihood by the treating ED physician. Integrated clinical judgment was quantified using a visual analogue scale at 90 minutes after patient's presentation to the ED. The primary diagnostic endpoint was index AMI. Results Among 2031 patients, 417/2031 patients (20.5%) had at least one MACE within 30 days. Prognostic accuracy for 30-day MACE quantified by the area under the receiver-operating characteristics curve (AUC) was 0.87 (95% CI 0.85–0.89) for T-MACS, 0.87 (95% CI 0.85–0.89) for HEART, 0.84 (95% CI 0.82–0.86) for GRACE, 0.81 (95% CI 0.79–0.83) for TIMI, 0.75 (95% CI 0.73–0.78) for EDACS, versus 0.89 (95% CI 0.87–0.91) for simple integrated clinical judgment (p<0.01 versus GRACE, TIMI, and EDACS; Figure 1). Similarly, diagnostic accuracy was 0.92 (95% CI 0.90–0.94) for T-MACS, 0.89 (95% CI 0.87–0.90) for HEART, 0.88 (95% CI 0.86–0.89) for GRACE, 0.80 (95% CI 0.78–0.82) for TIMI, 0.74 (95% CI 0.72–0.77) for EDACS, versus 0.89 (95% CI 0.88–0.91) for simple integrated clinical judgment (p<0.01 versus GRACE, TIMI, and EDACS). Conclusion None of the formal clinical risk scores outperformed simple integrated clinical judgment for ACS in the prediction of 30-day MACE or the diagnosis of AMI. Therefore, in the era of hs-cTn testing as part of integrated clinical judgment, clinical risk scores seem to no longer provide incremental value. Figure 1. Diagnostic accuracy for MACE at 30-days Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): Swiss National Science Foundation, Swiss Heart Foundation


2020 ◽  
pp. 102490792094407
Author(s):  
Hasan Aydin ◽  
Yasin Ozpinar ◽  
Ulas Karaoglu ◽  
Muhittin Issever ◽  
Huseyin Aygun ◽  
...  

Introduction: The aim of this study was to determine the risk assessment of acute coronary syndrome and prediction of major adverse cardiac events by HEART (History, ECG, Age, Risk factors, Troponin) and HEARTS3 (HEART + 3S = Sex, Serial 2-h ECG, and Serial 2-h delta Troponin) scoring systems in patients admitted to the emergency department with chest pain. Methods: This is a single-center prospective cohort study. This study was conducted in patients admitted to the emergency department with chest pain, without ST-elevation myocardial infarction, who were 18 years or older, and agreed to participate in the study. The primary endpoint is the occurrence of major adverse cardiovascular events within 30 days. The receiver operating characteristic curve was used to assess the power of HEART and HEARTS3 scores to predict major adverse cardiovascular events. Results: The mean age of 239 patients was 47.91 ± 13.93 years and 72.4% (173) were male. Major adverse cardiovascular events developed in 20.1% (48) of the patients. The mean HEART and HEARTS3 scores of the patients with major adverse cardiovascular events (5.67 ± 1.46 and 9.38 ± 3.91, respectively) were both statistically and significantly higher than the scores of the patients without major adverse cardiovascular events (2.33 ± 1.44 and 2.22 ± 1.39; p = 0.001). The area under the curve values of HEART and HEARTS3 scores were found to be 0.943 (95% confidence interval: 0.905–0.968) and 0.990 (0.968–0.999), respectively. Conclusion: In our study, the power of HEARTS3 score to predict major adverse cardiovascular events was better in the risk assessment of acute coronary syndrome in patients admitted to the emergency department with chest pain compared to the HEART score. We think that patients with a low HEARTS3 score can be safely discharged from emergency department without further cardiac examination.


Sign in / Sign up

Export Citation Format

Share Document